Jade Biosciences, Inc. (NasdaqCM: JBIO)
Health Care · Biotechnology · US
$21.84
-11.61% today · +229.5% 1Y
Jade Biosciences, Inc. (NasdaqCM: JBIO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.57B and employs 55 people.
Over the last twelve months the share price has gained 229.5%, trading between 6.67 and 28.00.
Tweenvest scores Jade Biosciences, Inc. across four factors: quality 26/100. Its strongest factor is quality.
JBIO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.57B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.11
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $28.00
- 52-week low
- $6.67
- Avg volume (3M)
- —
- Shares outstanding
- 63.60M
- Employees
- 55
- Next earnings
- —
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
- ISIN
- US0080642061
- Listed since
- Jun 30, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.